Pipeline
These networks have granted us access to large-scale GMP cell manufacturing facilities and reaching out to patients from diverse backgrounds.
BioSyngen has partnered with an extensive hospital network as well as received support from both the public sector and private enterprises in China and Singapore.
PRODUCT
INDICATIONS
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
BRG01
First-in-Class
Nasopharyngeal cancer
EBV+ Hematologic malignancies
BST02
Best-in-Class
Liver cancer(all types)
BRL03
First-in-Class
Multiple solid tumors (incl. Lung)
BGT007
First-in-Class
CRC, GC, EC&PDAC
Multi-specific antibodies
First-in-Class
Multiple solid tumors
Allo-cel
First-in-Class
Multiple solid and liquid tumors
First-in-Class
Nasopharyngeal cancer
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
EBV+ Hematologic malignancies
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
Best-in-Class
Liver cancer(all types)
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
First-in-Class
Multiple solid tumors (incl. Lung)
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
First-in-Class
CRC, GC, EC&PDAC
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
First-in-Class
Multiple solid tumors
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
First-in-Class
Multiple solid and liquid tumors
 PRE-CLINICAL
          IIT
 PHASE 1/     PHASE 2
WORK WITH US
Take part in our mission to deliver more effective cancer care and improve patient outcomes.